Stayble Therapeutics AB (STABL) — Cash Flow-to-Debt Ratio
Stayble Therapeutics AB (STABL) has a Cash Flow-to-Debt Ratio of -0.79x as of December 2025, meaning its operating cash flow of Skr-1.34 Million could theoretically repay -1% of its total liabilities (Skr1.70 Million) in one year. See Stayble Therapeutics AB free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Stayble Therapeutics AB Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for Stayble Therapeutics AB across 10 annual periods. Also explore Stayble Therapeutics AB annual equity growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Stayble Therapeutics AB (2016–2025)
Year-by-year debt coverage analysis for Stayble Therapeutics AB. For market capitalisation and broader financial context, see STABL market cap.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.96x | Skr-6.72 Million | Skr1.70 Million | ▲ +35.7% |
| 2024 | -6.15x | Skr-14.67 Million | Skr2.38 Million | ▼ -35.8% |
| 2023 | -4.53x | Skr-23.54 Million | Skr5.19 Million | ▲ +29.6% |
| 2022 | -6.44x | Skr-24.89 Million | Skr3.87 Million | ▼ -156.0% |
| 2021 | -2.51x | Skr-9.63 Million | Skr3.83 Million | ▲ +74.3% |
| 2020 | -9.80x | Skr-23.98 Million | Skr2.45 Million | ▼ -33999.6% |
| 2019 | 0.03x | Skr289.39K | Skr10.01 Million | ▲ +101.0% |
| 2018 | -2.87x | Skr-5.42 Million | Skr1.89 Million | ▼ -32.9% |
| 2017 | -2.16x | Skr-2.62 Million | Skr1.21 Million | ▼ -70.5% |
| 2016 | -1.27x | Skr-1.39 Million | Skr1.10 Million | — |